Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia parecoxib

Executive Summary

Pharmacia will submit additional data to FDA in 12 to 18 months following July 13 "not approvable" letter for its injectable COX-2 inhibitor parecoxib. The letter "indicated that there were deficiencies in the application," and requested confirmatory data, Pharmacia said. The application was filed in September 2000

You may also be interested in...



Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”

Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn

Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”

Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn

Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug

Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel